When: Price reaches $173-$175 without volume confirmation within five sessions

Then: trim 25-30% of position

HOLD with explicit trim authorization into $173-$175 resistance if breakout fails within 3-5 sessions; Buy reserved for confirmed breakout with three simultaneous gates met

• Forward EPS consensus of $9.80 implies 74% rebound from $6.00 trailing EPS requiring nearly recreating FY2022 pre-Solventum peak of $10.18 from structurally smaller $25B revenue base (vs $35B legacy)
• Price $169.55 below declining 50 SMA at $173.03; MACD cross just occurred with both lines below zero; RSI neutral at 50.88 represents mean reversion off September 14 sub-30 oversold
• VWMA collapsed from $180 to ~$165 over down-leg, meaning average buyer over past months is underwater
• Working capital headwind of $3.2B not confirmed as litigation roll-off in company guidance; $402M restructuring charge still running through 2025
• $3.4B gap between capital returns and FCF funded by balance-sheet drawdown; CEO warns PFAS 'keeps resurfacing'
• 10-year at 5% and 30-year at highest level since 2004 represents regime change in discount rate compressing equity multiples mechanically
• 97% odds of no 2026 cuts; 90% odds of another rate hike is opposite of easing environment supporting prior multiple expansion
• Combat arms earplug liability escalated from ~$1B to over $5B before resolution; PFAS is materially larger in scope with demonstrated track record of escalation beyond initial expectations
• Linear 1.6 to 1 reward-to-risk ratio (6% downside to 200 SMA vs 9.6% upside to $185.75 fair value) invalidates in fat-tail scenario; adverse PFAS ruling can produce 15-25% drawdowns in days
• Position sizing capped at 30-40% of typical (conservative vs trader's 50%) given macro and litigation tail risk
• Buy authorization requires daily close above $173.74 on more than 4 million shares AND forward EPS revision confirmation AND no fresh adverse PFAS news in prior 5 sessions

→ vs aggressive: Forward EPS consensus of $9.80 is a forecast, not a fact; company guidance does not confirm litigation tail-off in 2026; reaching $9.80 from structurally smaller $25B revenue base requires extraordinary margin expansion not evident in normal channels

→ vs aggressive: Technical 'coiling base' is actually a declining ceiling; 50 SMA peaked mid-August near $178 and is rolling over; MACD cross below zero and RSI neutral indicates relief bounce, not upside conviction

→ vs aggressive: Macro dismissal is incorrect; 10-year at 5% and 30-year at highest level since 2004 mechanically compresses equity multiples through present-value calculus regardless of revenue impact; industrial multiples compressed in past hawkish cycles even without recession

→ vs aggressive: PFAS 'priced in' framing is market timing, not risk management; combat arms earplug liability escalated 5x beyond initial estimates; PFAS has demonstrated track record of escalating beyond initial expectations with CEO acknowledging ongoing resurfacing

→ vs aggressive: 1.6 to 1 reward-to-risk ratio is misleading; downside probability is materially higher in hawkish macro with PFAS tail risk; fat-tail adverse settlement events invalidate linear calculation

→ vs aggressive: Maximum 50% sizing is insufficient given conditions; recommends 30-40% given macro and litigation tail until confirmation gates clear

HOLD with three specific refinements: trim 25-30% of position if price reaches $173-$175 without volume confirmation within five sessions; simplify buy trigger to two gates (daily close above $173.74 on more than 4 million shares plus either forward EPS revision confirmation OR 10-year yield below 4.7%, removing PFAS news gate); cap breakout-add positions at 50% of typical size. Stop remains at $159.44.

• FCF trajectory is $5.07B (2023) to $638M (2024) to $1.4B (2025), not a clean recovery—post-Solventum baseline likely $1.4B to $2.5B versus $4.8B capital return cadence
• 2025 had $402M non-recurring restructuring charge; operating margin improved from 16.7% (2022) to 19.6% (2024)
• $9.80 forward EPS requires both continued margin expansion AND stable macro; macro is the bigger risk to consensus than fundamentals
• Technical setup: 200 SMA support, fresh MACD cross, RSI recovering from sub-30, price above 10 EMA and VWMA—this configuration differs from typical relief bounces
• Three-gate trigger overconditioned; PFAS is a recurring feature of the name, not exceptional—third gate will almost never clear
• Conservative analyst's recession odds of 10% conflict with industrial multiple compression forecast of 2-4 turns due to duration risk—internally inconsistent
• Aggressive analyst's 50 SMA overhead resistance view conflicts with adding on confirmed breakout without explaining why breakout inverts risk equation
• Trim 25-30% if price hits $173-$175 without volume confirmation within five sessions
• Simplified buy trigger: price above $173.74 on >4M shares plus either EPS revision or 10-year yield below 4.7%
• Breakout-add capped at 50% of typical position size due to higher breakout failure rates in hawkish macro regimes
• Stop at $159.44 remains firm

→ vs aggressive: FCF recovery is messier than presented; baseline $1.4B-$2.5B cannot sustainably fund $4.8B capital return cadence—the treadmill critique is alive, just slower

→ vs aggressive: Calling $9.80 EPS rebound a 'rearview mirror concern' is intellectually lazy—the real issue is it requires both margin expansion and stable macro, not that the number is wrong

→ vs aggressive: 50 SMA at $173 as overhead resistance conflicts with adding on confirmed breakout; has not articulated why breakout above that level inverts the risk equation

→ vs conservative: Four bullish technical indicators 'relief bounce' statistic is meaningless without context; this specific configuration (200 SMA support, MACD cross, RSI from sub-30, price above 10 EMA and VWMA) differs from typical relief bounces

→ vs conservative: Three-gate buy trigger is overconditioned into uselessness; PFAS gate will almost never clear since PFAS headlines are a recurring feature, not exceptional—effectively waiting for perfect information in an imperfect environment

→ vs conservative: Cannot use 10% recession odds to support aggressive growth thesis while simultaneously forecasting industrial multiple compression of 2-4 turns from duration risk; these arguments work against each other